

Yun-Choi Hye Sook, Lee Duck Hyung, Ryu Jae Chun, Ki Churl Chang

Department of Pharmacology, College of Medicine, Gyeongsang National University, Natural Product Research Institute, Seoul National University, Department of Chemistry, Sogang University, Institute of Science and Technology, Seoul

In the present study, the effects of THI 52 on NO production, and tumor necrosis factor (TNF)- $\alpha$ , and iNOS mRNA expression were investigated in RAW 264.7 cells exposed to LPS plus IFN- $\gamma$ . In addition, the effects of THI 52 on vascular reactivity in vitro and ex vivo, and iNOS protein expression (rat lung) were investigated in LPS-treated rats. Treatment of THI 52 concentration-dependently reduced not only NO production ( $IC_{50}$  value, 12.5  $\mu$ M) but also the expression of TNF- $\alpha$ , and iNOS mRNA in RAW 264.7 cells. Incubation of rat endothelium-removed thoracic aorta with LPS (300 ng/ml) for 8 h in vitro resulted in suppression of vasoconstrictor effects to phenylephrine (PE), which was restored by co-incubation with THI 52. Treatment THI 52 (15 and 20 mg/kg, i.p) 30 min before injection of LPS (10 mg/kg, i.p) resulted in significant reduction of the expression of iNOS protein in rat lung tissue, and restoration of vascular contractility to PE. Plasma NOx level was significantly ( $p < 0.01$ ) reduced by THI 52 (15 and 20 mg/kg, i.p) in LPS-treated (10 mg/kg, i.p) rats. THI 52 concentration-dependently diminished the NF- $\kappa$ B-DNA complex, which is essential for expression of inflammatory genes. Using CCL1 cells, a TNF- $\alpha$  sensitive L929 fibroblast cell line, effect of THI 52 on TNF- $\alpha$  toxicity was measured. Inclusion of THI 52 significantly increased the cell viability, indicating THI 52 reduces TNF- $\alpha$  secretion to the media. These results strongly suggest that THI 52 can suppress both TNF- $\alpha$  and iNOS gene expression induced by LPS + IFN- $\gamma$  in RAW 264.7 cells at the transcriptional level, and restore the vascular contractility to PE. Thus, THI 52, a new synthetic isoquinoline alkaloid, may be beneficial in inflammatory disorders where production of NO is exceeded by iNOS expression (This work was supported by HMP98-D-4-0045)

[PA1-11] [ 10/18/2001 (Thr) 14:00 - 17:00 / Hall D ]

### Inhibition of TNF- $\alpha$ and IL-6 production by aucubin through blockade of NF- $\kappa$ B activation in RBL-2H3 mast cells

Jeong HyunJa<sup>o</sup>, Shim KyungShik, Kim KyungSuk, Kim HyungMin

Department of Oriental Pharmacy, College of Pharmacy and Center of Oriental Medicinal Science, Wonkwon University, Division of Biological Sciences, College of Natural Science, Chonbuk National University

IgE-stimulated mast cells induce synthesis and production of cytokines including tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-6 with proinflammatory and immune regulatory properties. Expression of TNF- $\alpha$  and IL-6 proteins is dependent on the activation of a transcription factor, nuclear factor (NF)- $\kappa$ B. The iridoid glycoside, aucubin, has been found as a natural constituent of many traditional oriental medicinal plants. We studied the effect of aucubin on the TNF- $\alpha$  and IL-6 expression in IgE-stimulated rat basophilic leukemia (RBL)-2H3 mast cells. We show that aucubin inhibited IgE-induced TNF- $\alpha$  and IL-6 production and expression in RBL-2H3 cells. Aucubin also inhibited IgE-induced nuclear translocation of p65 subunit of NF- $\kappa$ B and degradation of I $\kappa$ B $\alpha$ . Inhibition of NF- $\kappa$ B activation by aucubin might be specific since activator protein-1 binding activity was not affected. In conclusion, these results suggest that aucubin is a specific inhibitor of NF- $\kappa$ B activation in mast cells, which might explain its beneficial effect in the treatment of chronic allergic inflammatory diseases.

[PA1-12] [ 10/18/2001 (Thr) 14:00 - 17:00 / Hall D ]

### DA-8159, a New Phosphodiesterase 5 Inhibitor, Induces Erection in the Anesthetized Dogs

Kim DongSung<sup>o</sup>, Oh TaeYoung, Ahn ByoungOk, Yoo Moochi, Kim WonBae

Research Laboratories, Dong-A Pharm. Co. Ltd., Korea